Clinical trial
Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women
NCT00205777 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00205777 |
|---|---|
| Title | Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women |
| Official title | Fracture Incidence Reduction And Safety Of TSE-424 (Bazedoxifene Acetate) Compared To Placebo And Raloxifene In Osteoporotic Postmenopausal Women |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug, Other |
| Interventions | Bazedoxifene Acetate, Placebo |
| Enrollment | 7,609 |
| Start date | Dec 1, 2001 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Sep 20, 2005 |
| Last update posted | Apr 10, 2013 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Croatia, Denmark, Estonia, Finland and 18 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: